📑Reagensi za analizu klinickog egzomana MiSeq aparatu
Procurement process summary
This process is to purchase Reagensi za analizu klinickog egzomana MiSeq aparatu.
This contract was awarded by 🇭🇷 Klinika za dječje bolesti Zagreb for an amount of HRK 2,120,665 to 1 supplier. It was published on 2022-05-06 through open
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
Buying entity🇭🇷 Klinika za dječje bolesti Zagreb Buying unitnot reported Publication date2022-05-06 Contest statusnot reported DescriptionReagensi za analizu klinickog egzomana MiSeq aparatuAwards
This award was granted to KEFO d.o.o. by Klinika za dječje bolesti Zagreb for an amount of HRK 2,120,665. The procurement process was conducted through open for the category of goods. The award was granted on 2022-06-27. This is award number 1.
| Supplier | Amount | Award date | Award number |
|---|---|---|---|
| 🇭🇷 KEFO d.o.o. | HRK 2,120,665 | 2022-06-27 | 1 |
Market context and opportunities
The execution of this contract allows the entity Klinika za dječje bolesti Zagreb to fulfill its public service objectives efficiently.
The open purchase modality ensures that the process is transparent and compliant with regulations.
Transparency in this process is reflected in the detailed publication of all aspects of the contract and its results.
This transparency in public procurement promotes fair competition, prevents corruption, and ensures that public resources are used efficiently for the benefit of citizens.
Additional data
Contract NumberHR_ocds-70d2nz-44f54a23-94ae-447e-b190-254c481ceb38-award-1Publication date2022-05-06Contract datenot reportedAward date2022-06-27CategoriesgoodsPurchase modalityopenMethod detailspt_openStatusnot reportedData sources
Sociedad.info publishes data from official sources, in compliance with public information access laws. Public access to this data is a civic right that helps hold government accountable. This data, including names and identifiers, is already public in the official source. Read our privacy policy.
